BACKGROUND Left atrial appendage closure (LAAC) was approved by the U.S. Food and Drug Administration (FDA)
Together, those trials demonstrated that the device was noninferior to warfarin for the primary composite endpoint of stroke, systemic embolism, or cardiovascular death. Furthermore, device implantation was associated with an approximately 80% reduction in hemorrhagic strokes and a >50% reduction in cardiovascular death (2) (3) (4) (5) (6) .
In February 2016, the U.S. Centers for Medicare & Medicaid Services finalized its coverage decision, requiring all patients undergoing LAAC to be included into a prospective national registry (7) . However, the first such LAAC registry was only certified in August 2016; accordingly, the majority of LAAC procedures performed since FDA approval have not been included into any national registry (8) . This is important because it would be expected that the highest complication rate with a novel technology/ technique such as LAAC would occur at its initial introduction into clinical practice.
Despite the absence of a prospective registry from the time of FDA approval, we were nonetheless able to collect procedural data on all LAAC procedures since approval. In brief, the manufacturer required a clinical specialist be present at all cases and for procedural parameters and major complications to be collected and reported using a standardized process and forms. Herein, we report the comprehensive procedural outcomes and acute procedure-related complication data for consecutive LAAC cases since FDA approval.
METHODS
THE LAAC DEVICE. The Watchman device (Boston Scientific, Inc., Natick, Massachusetts) has been previously described (9) . In brief, the device is a self- Reddy et al.
Safety of Post-Approval LAA Occlusion Device Implantation Table 1 ). In two-thirds of these instances (n ¼ 24), the effusions were successfully drained percutaneously; the remaining (n ¼ 12) required surgery, and 3 patients did not survive (see below). An additional 11 patients (0.29%) developed pericardial effusions that did not require intervention but instead only conservative management.
Three strokes (0.08%) and 3 deaths (0.08%) were attributed to the procedure. Two of the strokes presented with symptoms consistent with ischemic stroke (inability to use arm and right-sided weakness).
The other stroke presented the day after the procedure, and a head computed tomographic scan revealed a hemorrhagic bleed. All 3 deaths were secondary to pericardial effusions related to LAA perforation by the device. One patient died during pericardiocentesis before surgery could be performed, 1 died during surgery, and 1 died 2 days after surgical repair. In addition, 1 patient died within 7 days of the procedure from a pulmonary embolism unrelated to the device.
There were 9 instances (0.24%) of device embolization ( Table 2) ; two-thirds of these (n ¼ 6) required surgical removal, whereas the remaining third (n ¼ 3)
were removed percutaneously. All but 1 of the device embolizations were identified either during the procedure (n ¼ 5) or while the patient was recovering in the hospital (n ¼ 3). The last embolization was discovered during the routine 45-day TEE; this device was percutaneously removed within 24 h. (Table 3) , have been concordant in demonstrating the noninferiority of the LAAC device to warfarin for stroke or systemic embolism and its superiority in reducing hemorrhagic stroke, cardiovascular mortality, and nonprocedure-related bleeding (2) (3) (4) (5) (6) 10, 12) . In addition, the device has been found to result in improved quality of life (13) . In a detailed cost-effectiveness analysis that incorporated the economic impact of strokes as a function of their resulting level of disability, LAAC demonstrated dominance over both warfarin and the class of Reddy et al. Tables 1 and 2 . Reddy et al. (Table 3) . Abbreviations as in Tables 1 to 3 .
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Safety of Post-Approval LAA Occlusion Device Implantation (Table 4) .
Finally, procedure-related mortality has been infrequent throughout the Watchman LAAC experience ( Table 4 ). In the aggregate Watchman LAAC experience, procedure-related mortality was only 0.06%, which translates to only 1 death per 1,680 patients (Table 4) 
